Analysis of the efficacy of baricitinib in bone erosion assessed by HR-pQCT in rheumatoid arthritis.
Not Applicable
Recruiting
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000033150
- Lead Sponsor
- agasaki University Graduate School of Biomedical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
1.Pregnant patients 2.The patients who cannot rest the extremities during taking HR-pQCT. 3.The patients who is treated with prednisone >10mg 4.The patients who are taking intraarticular corticosteroid injection into evaluation joints within 6 months before enrollment. 5.The patients who are complicated with other disease which can affect evaluation joint. 6.In the opinion of the investigator, the patients who is not suitable for this study for other reasons.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of volume of bone erosion in RA treated by baricitinib and csDMARDs which detected by HR-pQCT from baseline to 12 months.
- Secondary Outcome Measures
Name Time Method 1.To evaluate the change of bone microarchitecture using HR-pQCT from baseline to 12 months. 2. To investigate the relation between HR-pQCT and finding of other modality such as musculoskeletal ultrasonography. 3, To investigate the relation between HR-pQCT and biomarkes measured by multiplex bead assays.